###### Significance of the study

What is already known about this subject?
=========================================

-   Available evidence shows an increasing prevalence of diabetes mellitus (DM) and diabetic retinopathy (DR) in India.

What are the new findings?
==========================

-   This study which is first such in over a decade, reports high prevalence of both DM and DR in a western Indian population with a sizeable proportion of urban poor. It also demonstrates significant proportion of unidentified cases of DM and poor coverage of DR screening in an urban region with good access to healthcare.

How might these results change the focus of research or clinical practice?
==========================================================================

-   These results emphasise the need of evidence generation on prevalence of DM and DR from rural as well as other urban regions of India and to identify strategies to improve screening coverage for detection of DM and DR.

Introduction {#s1}
============

India is home to over 74 million diabetics, and the number is estimated to exceed 123 million by 2040.[@R1] Increasing longevity, changing lifestyle and dietary habits contribute to increasing prevalence of diabetes mellitus (DM) in India and all over the world.[@R2] Largest increase in the disease burden (among all non-communicable diseases) between the year 1996 and 2016 was noted for DM at 80%.[@R3] Diabetes and its complications are now an area of focus for prevention of mortality and morbidity. Absence of acute symptoms and lack of awareness are the main barriers for detection of DM and its complications.[@R4]

Prevalence of DM in India has been reported to be between 10.2% and 36% in various population-based surveys.[@R6] However, there was a variation in the age group included and the methodology used in these surveys. A multistate survey to establish prevalence of DM published in 2010 reported age-specific prevalence of DM. Prevalence in population above 55 years of age in Maharashtra state (where present study was conducted) was 25% for men and 20% for women.[@R6]

Diabetic retinopathy (DR) is a microvascular complication of DM and can cause blindness or visual impairment (VI). Although cataract remains a principal cause of blindness in India, other retinal causes (especially DR) are emerging as priority diseases for national programme for control of blindness (NPCB)[@R10] as well as vision 2020 India.[@R11] Prevalence of DR among diabetics has been reported to be 9.6%--21.7% in various studies conducted across India over the last decade.[@R12] Previous DR surveys have been conducted largely in south and central India. Also, the age groups included and the methodology used was widely variable making direct comparison impossible. Moreover, there is likely to be a variation in the prevalence across states of India due to differences in levels of urbanisation which can affect lifestyle of the population. This study was conducted in Pune municipal corporation area (population 3 million, 16% persons \>50 years of age)[@R17] of the Maharashtra state of western India. Pune is the second largest city in the state and is a hub for education, automobile and information technology industry. Due to a sizeable proportion of slum dwellers (40%), large migrant population from other states and rapidly changing lifestyle, the population forms a 'high risk' group for DM. There is no available data guiding the implementation of DR services in the city. This study therefore aims to provide a baseline data to plan the DR services in the city to achieve better blindness prevention. In Pune, there are nearly 400 ophthalmologists and over 25 DR screening and treatment centres of which most (24) are in the private sector (personal communication). In India, private expenditure (including out of pocket payments) constitutes 70% of total health expenditure and 61% of inpatient episodes or hospital visits are in the private sector.[@R18] Where the private sector dominates the health system, the poor struggle to access fee-for-service care.[@R19]

Rapid assessment of avoidable blindness (RAAB) is a survey methodology designed for assessment of prevalence and causes of blindness and VI in population over 50 years of age.[@R20] It has been used in over 200 population surveys of eye health worldwide.[@R22] Later DR module was added to the original RAAB methodology[@R22] which allows estimation of prevalence of DM and DR in a high risk population. This survey was planned with the objectives of estimating prevalence and causes of blindness as well as prevalence of DM and DR in Pune. The findings related to DR module of the survey will be presented in this paper. To the best of the authors' knowledge, this is first such survey in India.

Methods {#s2}
=======

This cross sectional survey used RAAB+DR methodology. Each survey team consisted of an ophthalmologist (minimum 1 year experience of working in the retina department with a focus on DR), an optometrist, a study coordinator and a technician. Three such teams were trained for a week by a certified RAAB trainer. At the end of the training, each team underwent inter observer variability (IOV) testing to check agreement on visual acuity assessment and diagnosis of DR between each team and a gold standard (a senior ophthalmologist). A kappa value of 0.6 or more was considered as acceptable. Kappa values of IOV for visual acuity assessment and DR assessment were 0.87 and 0.65 respectively.

Sampling {#s2-1}
--------

This study was undertaken in Pune municipal area between[@R17] June and August 2017. Previous studies in India have estimated the prevalence of DM in the population aged 50 and above at 15%[@R6] and that 25% of this group experience DR.[@R14] A sample size of 3527 participants age 50 and above was calculated based on an expected prevalence of DR of 3.8%[@R14] in general population of this age group, precision of 22% of the estimate (0.84%) (considering the time, logistics and seasonality of area in order that survey could be completed yielding valid results.), non-compliance of 10%, 95% confidence and a design effect of 1.6.

Therefore, 60 clusters consisting of 60 participants each needed to be examined. Clusters were selected using probability proportionate to size sampling (cluster with a higher population had more chance of getting selected). Updated data from the electoral list of 2017 was used as the sampling frame. The detailed methods of RAAB +DR are presented elsewhere.[@R22] Each cluster was divided into multiple segments each having approximately 60 persons above 50 years of age (compact segment sampling). Local community leaders helped in segmentation and random selection of a segment using a folded chit lottery method. The survey coordinator publicised the date and time of visit at least a day prior to minimise non-response. Two teams then visited separate areas (door to door visit) in the segment until they examined 30 persons each. If an enumerated person was not available, the team made a repeat visit at the end of the day to check the availability. In the selected segments having high rise apartments, each consecutive house was visited until target of 30 enumerations was achieved by each team.

Examination and data collection {#s2-2}
-------------------------------

Data on occupational and health insurance status were collected in the two additional fields provided in the standard RAAB data forms. All participants then underwent presenting and pinhole visual acuity testing in each eye using Snellen's tumbling E chart. Participants were labelled as having normal vision, early/moderate/severe VI or blindness as per WHO's convention and the RAAB survey methodology V.6. All participants then underwent anterior segment evaluation with a light source, and a brief lens examination for red glow by direct ophthalmoscope. All eyes with early VI (\<6/12) or worse were examined with a torch and a direct ophthalmoscope (in a darkened room in the house of the participant) to ascertain the cause. In the participants who were not dilated, if no anterior segment or obvious posterior segment cause was identified, eyes were labelled as having other posterior segment disease.

Following WHO convention, the principal cause of VI/ blindness was defined as the disorder most amenable to treatment or prevention.[@R24] If there was a primary and a secondary cause, the primary cause was selected as the principal disorder.[@R25] For example, participants with VI resulting from cataract and other disease (such as DR) were labelled as having cataract as the primary cause.

All participants who consented then underwent a random blood sugar level (RBSL) test. Self-reported diabetics and those with RBSL of ≥200 mg (newly diagnosed diabetics) were examined for DR after pupillary dilatation. Retinal examination was carried out with indirect ophthalmoscope (Appasamy Associates, Chennai, India) and 20D lens (Volk, Germany) after a minimum 30 min of dilatation. Meanwhile survey team continued visiting other houses for data collection before coming back to perform indirect ophthalmoscopy in dilated individuals. Assessment of DR was completed by a trained ophthalmologist. The Scottish classification was used for grading retinopathy and maculopathy.[@R26] Those with proliferative changes and macular oedema involving the centre were classified as having sight threatening DR (STDR). All self-reported diabetics were asked about the timing of last retina evaluation in order to determine DR screening coverage. All participants identified with a treatable cause of blindness or VI were referred to the base hospital for further management.

Data entry and analysis {#s2-3}
-----------------------

Data were entered into the RAAB6 software on a daily basis by two separate data entry operators (double entry) to ensure validity and consistency. Descriptive statistics were generated by RAAB6 software. Statistical tests of association were carried out in a statistical software (STATA IC V.14, StataCorp).

Results {#s3}
=======

The response rate was 89.5% (3221/3600), 55.3% were females. Gender representation in the age group 50--59 years was 41.9% (604/1440) men vs 47.2% (841/1781) women. In other age group categories, characteristics of respondents such gender were equally distributed. Among respondents, a further 6% (203/3600) who were not known diabetics refused blood test---most of these (173/203, 85.2%) being from younger age group of 50--59 years.

The prevalence of DM in the sample was (706/3221) 21.9 %(95 CI 20.1 to 23.7). Prevalence of DM by age and gender is shown in [table 1](#T1){ref-type="table"}.

###### 

Prevalence of diabetes by age group and by gender

  Age (years)   Men   Women                 Total                               
  ------------- ----- --------------------- ------- --------------------- ----- ---------------------
  50--59        115   19.0 (15.8 to 22.3)   157     18.7 (16.0 to 21.4)   272   18.8 (16.7 to 20.9)
  60--69        128   25.5 (21.2 to 29.9)   158     26.2 (22.5 to 29.9)   286   25.9 (23.2 to 28.6)
  70--79        64    26.0 (19.9 to 32.2)   57      24.5 (17.9 to 31.0)   121   25.3 (20.4 to 30.1)
  80+           15    16.9 (10.3 to 23.4)   12      11.5 (6.5 to 16.6)    27    14.0 (9.8 to 18.2)
  All ages      322   22.4 (19.7 to 25.0)   384     21.5 (19.3 to 23.8)   706   21.9 (20.1 to 23.7)

\*Known and newly diagnosed diabetes mellitus.

Of the total 706 diabetics, 127 (18%) were newly identified. Of the 579 self-reported diabetics, 256 (44.2%) had RBSL of \>200 mg/dL. Coverage of treatment for DM was 96.4% (558/579). Most (514/579, 88.8%) were on oral hypoglycaemic drugs. Twenty one (3.6 %) did not receive any antidiabetic treatment.

*DR screening coverage*: most diabetics (401/579, 69.3%) never had a screening for DR in the past and 19% (110/579) had one in last 12 months.

Nearly a third (237/706, 33%) diabetics refused to undergo dilatation required to determine status of DR. The data were stratified by occupational status (daily wage workers vs fixed income/business) and health insurance status (yes/no). There was a very strong evidence to suggest that daily wage workers and uninsured persons were less likely to undergo DR screening compared with others (p\<0.001).

Prevalence of any retinopathy/maculopathy among diabetics was 14.3% (95% CI 11.7 to 16.9) and that of STDR was 3.1% (95% CI 1.9 to 4.3). The proportion of dilated participants who had any sign of retinopathy/maculopathy was 21%, STDR was 3.1% and that of lasered DR was 2.7%. Prevalence by grades of DR among diabetics and in full sample is shown in [table 2](#T2){ref-type="table"}.

Prevalence of VI and blindness among diabetics is shown in [table 3](#T3){ref-type="table"}.

Causes of blindness and VI among diabetics are shown in [table 4](#T4){ref-type="table"}.

###### 

Prevalence of DR in diabetics and in entire sample

  Retinopathy grade                         n     Among diabetics        Full sample
  ----------------------------------------- ----- ---------------------- ----------------------
  No retinopathy (R0)                       379   53.7% (49.4 to 58.0)   11.8% (10.4 to 13.2)
  Background DR---mild (R1)                 50    7.1% (5.2 to 8.9)      1.6% (1.1 to 2.0)
  Background DR---observable (R2)           11    1.6% (0.7 to 2.4)      0.3% (0.2 to 0.5)
  Background DR---referable (R3)            13    1.8% (0.6 to 3.0)      0.4% (0.1 to 0.7)
  Proliferative DR (R4)                     14    2.0% (1.1 to 2.9)      0.4% (0.2 to 0.6)
  Ungradable DR (R6)                        4     0.6% (0.0 to 1.1)      0.1% (0.0 to 0.2)
  Any retinopathy                           92    13.0% (10.7 to 15.4)   2.9% (2.3 to 3.4)
  **Maculopathy grade**                                                  
  No maculopathy (M0)                       408   57.8% (53.5 to 62.1)   12.7% (11.2 to 14.1)
  Maculopathy---observable (M1)             35    5.0% (3.5 to 6.4)      1.1% (0.8 to 1.4)
  Maculopathy---referable (M2)              17    2.4% (1.4 to 3.5)      0.5% (0.3 to 0.8)
  Any maculopathy                           63    8.9% (6.9 to 11.0)     2.0% (1.5 to 2.4)
  Any retinopathy/maculopathy               101   14.3% (11.7 to 16.9)   3.1% (2.5 to 3.7)
  **Sight-threatening DR** (R4 and/or M2)   22    3.1% (1.9 to 4.3)      0.7% (0.4 to 0.9)
  Any laser scars                           19    2.7% (1.5 to 3.8)      0.6% (0.3 to 0.8)

DR, diabetic retinopathy.

###### 

Prevalence of VI and blindness among people with and without diabetes

                  Persons with diabetes   Persons without diabetes          
  --------------- ----------------------- -------------------------- ------ ---------------------
  Normal vision   494                     70.0 (65.2 to 74.7)        1719   68.3 (65.7 to 71.0)
  Early VI        114                     16.1 (12.9 to 19.4)        365    14.5 (12.9 to 16.1)
  Moderate VI     84                      11.9 (9.2 to 14.6)         356    14.2 (12.2 to 16.1)
  Severe VI       8                       1.1 (0.1 to 2.1)           35     1.4 (1.0 to 1.8)
  Blindness       3                       0.4 (0.0 to 0.9)           24     1.0 (0.5 to 1.4)

VI, visual impairment.

###### 

Causes of visual impairment among people with and without diabetes

                Blindness        Severe VI   Moderate VI   Early VI                                    
  ------------- ---------------- ----------- ------------- ---------- ---------- ---------- ---------- -----------
  Refr. error   0 (0)            1 (2)       0 (0)         1 (2)      12 (14)    47 (13)    46 (40)    168(46)
  Cataract      **3** (**50**)   18 (45)     8 (100)       26 (74)    57(67)     236 (66)   50 (43)    152(41)
  DR            0 (0)            0 (0)       0 (0)         0 (0)      3 (3)      0 (0)      0 (0)      0 (0)
  PSD           **1** (**16**)   17 (42)     0 (0)         3 (8)      7 (8)      37 (10)    9 (7)      18 (4)
  Other         2 (33)           4 (10)      0 (0)         5 (14)     5 (5)      36 (10)    9 (7)      27(7)
  Total         6 (100)          40 (100)    8 (100)       35 (100)   84 (100)   356(100)   114(100)   365 (100)

DM, diabetes mellitus; DR, diabetic retinopathy; PSD, posterior segment disorder.

All data relevant to the study are included in the article or uploaded as supplementary information ([online supplementary files 1-8](#SP1 SP2 SP3 SP4 SP5 SP6 SP7 SP8){ref-type="supplementary-material"}).

Discussion {#s4}
==========

India is one of the top two countries with high number of persons with DM.[@R1] Estimating prevalence of DM and DR is vital to planning, monitoring services and allocating resources for the same. Estimating proportion of diabetics in general population is possible only in a population-based survey and entails high cost and investment of resources and time. Adding DR module to a proven methodology of RAAB reduces the sample size without greatly affecting the accuracy of estimates.

Although response rate was good in the present study, there was slight over-representation of women especially in the younger (50--59 years) age group. This was because more men were away at work and hence unavailable on the day of survey.

Over one fifth (21.9%) of the participants had DM which extrapolates to 132 000 persons above 50 years of age having DM in Pune. Nearly 18% newly detected DM cases gives an estimate of 80 000 undetected cases of DM in Pune. However, there is a possibility of overestimation of prevalence as 6% persons without known diabetic status refused BSL examination. There was no significant difference in prevalence by gender. This proportion is higher than findings in previous studies from India.[@R6] The difference in the age groups of study sample may partly explain the higher prevalence in this study. A study conducted in south India[@R14] in population over 40 years had shown higher prevalence (28.2%). Different dietary habits in south India compared with western India might explain higher prevalence in that study. Prevalence of DM increased with increasing age up to 79 years thereafter falling down to a tenth. Wide 95% CI in 80+ age group indicates inadequate sample size and hence variable prevalence. Of the participants with DM, nearly a fifth were not aware of their status and almost half had uncontrolled BSL. This emphasises the need to create awareness of DM, improve access to diagnostic services for DM and DR especially in public hospitals for better case detection. Previous studies from India have reported poor awareness about DM among general population.[@R4] Persons with DM also need to be educated about importance of BSL control in reducing the risk of complications of DM.

Among known diabetics, coverage for treatment of DM was good (96.7%) but that for DR screening was poor. Over two-thirds of known diabetics had never received any eye examination for DR. Only a fifth had received DR screening in last 12 months. Indian guidelines recommend at least once a year retinal evaluation for all diabetics.[@R11] There was a very strong evidence to suggest that daily wage workers and uninsured persons were less likely to undergo DR screening. Screening for DR is a form of preventive health check-up available for a fees, hence persons belonging to lower socioeconomic strata were more likely to avoid it. Excellent coverage of treatment for DM indicates that people chose to receive medications for DM irrespective of socioeconomic status. This suggests that cost and lack of awareness could be important barriers for DR screening. Educating primary healthcare professionals such as physicians, general practitioners, pharmacists, laboratory personnel about the need and protocol for DR screening is perhaps the key to improve coverage of DR screening. Establishing DR screening programmes at diabetes clinics rather than at specialist eye hospitals might also help to improve screening coverage further.

Extrapolation of prevalence figures of DR (14.3%) and STDR (3.1%) among diabetics suggests, there are likely to be approximately 19 000 persons with DR and 5000 with STDR in Pune. Some participants refused to be dilated, hence these are likely underestimates. In a recent publication, Flaxman *et al* [@R27] have reported that globally crude prevalence (all age) of blindness due to all causes showed a declining trend except for DR which showed 7.7% increase. There was no statistically significant difference between prevalence of blindness and VI among diabetics and non-diabetics in this study. This could be because of good accessibility of services in this densely populated urban region.

Cataract was the principal cause of blindness (50% cases) followed by other posterior segment disorders (16%) among diabetics. This proportion among non-diabetics was 45% and 42% respectively. Risk of cataract among diabetics is higher than non-diabetics which could have been responsible for cataract being assigned as cause of blindness among them. DR as a cause of moderate VI was seen in 3% of diabetics. The causes of VI did not differ by DM status of the participants. None of the diabetic subjects was blind due to DR. However, this study was not powered enough to estimate prevalence of STDR. Additionally, there is a possibility of underestimation of DR as a cause of blindness/VI in diabetics as the disease most amenable to treatment (such as cataract) was labelled as the principal cause as per WHO convention.

There are certain limitations to this study. Over-representation of women especially in the younger age group could have resulted in selection bias. Every 1 in 20 participants refused RBSL test leading to possible overestimation of prevalence of DM. Nearly a third of diabetics refused dilated eye examination, adding potential downward bias to results. Conversely, the use of field-appropriate methods of diagnosis and grading may have led to an upward bias of results compared with a higher-end clinic-based equipment. Further analysis of known diabetics by their medication and DM control status would have helped study association between DR/STDR and DM control.

There is a definite need to increase awareness of DM among general population which will help in identifying a greater proportion of diabetics. Targeting diabetes clinics and use of telemedicine will improve coverage of DR screening. Referral linkages need to be established between diabetes clinics and DR treatment centres. There is need of similar RAAB plus DR survey in rural population as prevalence is known to differ.[@R6] Similar surveys in other parts of the state/country might fetch different results due to wide variation in dietary habits, lifestyles and are the need of the hour.

It is recommended that all stake holders be involved in increasing awareness, improving screening coverage and establishing referral linkages between screening and treatment centres. The findings of this study were disseminated through a meeting involving important stakeholders such as chief municipal health officer, district ophthalmic surgeon, secretary of the local branch of the Indian Medical Association, presidents of the local 'Diabetes Association' and senior citizen association etc. Results were also publicised through local print and electronic media to generate awareness about screening and treatment facilities. For improving access to DR treatment, a plan to link screening facilities in public sector to the treatment facilities in charitable organisations was submitted to municipal health authorities.

In conclusion, DM affects over fifth of persons above 50 years of age in urban India. Every seventh person with DM has DR, but coverage of screening is poor in Pune.
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